Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. | Verastem Oncology Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. | Blueprint Medicines Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders. | Agenus Agenus is an immuno-oncology company that focuses on the discovery and development of therapies for treating cancer. | Partner Therapeutics Partner Therapeutics is developing and commercializing cancer medicines and combination therapies. | Rakuten Medical Rakuten Medical (formerly Rakuten Aspyrian) is a clinical stage biotechnology company developing tumor-targeted precision therapies. | |
Founding Date | Founding Date 1998 | Founding Date 2010 | Founding Date 2011 | Founding Date 1994 | Founding Date 2017 | Founding Date 2013 |
Type | Type Public | Type Public | Type Public | Type Public | Type Private | Type Private |
Tags | ||||||
Locations | Locations San Diego, US HQ | Locations Needham, US HQ Walsrode, DE | Locations Cambridge, US HQ Amsterdam, NL Lugano, CH Zug, CH | Locations Lexington, US HQ Cambridge, GB Emeryville, US Berkeley, US Vacaville, US | Locations Lexington, US HQ Boston, US Lynnwood, US | Locations San Diego, US HQ Setagaya City, JP Amsterdam, NL Ecublens, CH Taipei, TW Taipei, TW San Mateo, US |
Employees | Employees 373157% increase | Employees 7328% increase | Employees 6552% increase | Employees 38927% decrease | Employees 1902% decrease | Employees 1191% decrease |
Valuation ($) | Valuation ($) 6.4 b | Valuation ($) 144.9 m | Valuation ($) 5.3 b | Valuation ($) 96.2 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | ||||||
Revenue (est.) | Revenue (est.) $829.3m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $249.4m (FY, 2023) | Revenue (est.) $156.3m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods $192.4m (FY, 2023) | Cost of goods N/A | Cost of goods $8.5m (FY, 2023) | Cost of goods $3.1m (FY, 2023) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $636.9m (FY, 2023) | Gross profit N/A | Gross profit $240.8m (FY, 2023) | Gross profit $153.2m (FY, 2023) | Gross profit N/A | Gross profit N/A |
Net income | Net income $281.6m (FY, 2023) | Net income ($87.4m) (FY, 2023) | Net income ($507m) (FY, 2023) | Net income ($257.4m) (FY, 2023) | Net income N/A | Net income N/A |
Operating ⚠ | ||||||
Phase II Trials Products | Phase II Trials Products 1 (FY, 2020) | Phase II Trials Products 4 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A |
Funding | ||||||
Latest funding round | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 60m (almost 7 years ago) | Latest funding round $ 100m (over 5 years ago) |
Total funding raised | Total funding raised $ 171.9m | Total funding raised $ 170m | Total funding raised $ 1.7b | Total funding raised $ 171.1m | Total funding raised $ 60m | Total funding raised $ 451.9m |